Serious Injury And Death Cases Involve Blood Clots Leading To DVT And/Or PE Events As Well As Heart Attacks And Strokes In Women Of Various Ages
UPDATE:"Merck to pay $100 million in NuvaRing contraceptive settlement" (2/7/14, Reuters)
The Form 10-Q SEC filing by Merck for the corporate quarterly period ending September 30, 2013 (93 page PDF document) provides us with this latest information about the number of filed NuvaRing lawsuits:
As previously disclosed, beginning in May 2007, a number of complaints were filed in various jurisdictions asserting claims against the Company’s subsidiaries Organon USA, Inc., Organon Pharmaceuticals USA, Inc., Organon International (collectively, “Organon”), and the Company arising from Organon’s marketing and sale of NuvaRing, a combined hormonal contraceptive vaginal ring. The plaintiffs contend that Organon and Schering-Plough, among other things, failed to adequately design and manufacture NuvaRing and failed to adequately warn of the alleged increased risk of venous thromboembolism (“VTE”) posed by NuvaRing, and/or downplayed the risk of VTE. The plaintiffs seek damages for injuries allegedly sustained from their product use, including some alleged deaths, heart attacks and strokes. The majority of the cases are currently pending in a federal multidistrict litigation (the “NuvaRing MDL”) venued in Missouri and in a coordinated proceeding in New Jersey state court.
As of September 30, 2013, there were approximately 1,715 NuvaRing cases....
Free NuvaRing Case Evaluation
Strictly Confidential, No Obligation.
In relevant part, in comparison, our last article about the NuvaRing litigation, "NuvaRing: Merck Updates On The Number Of Cases Filed Against Drug Company As Of June 30, 2013", reported this Merck information:
- As of June 30, 2013, there were approximately 1,500 NuvaRing cases
Next, the trial date for the first NuvaRing MDL "bellwether", or test, case (the Prather lawsuit) was moved from January 2014 to April 2014 by an Order issued by federal court Judge Rodney Sippel in October 2013 -- this being the latest in a series of first trial date postponements in this long-running NuvaRing litigation.
Lastly, we want to make you aware of an October 2013 revision to the FDA-approved Prescribing Information (aka, the package insert or label) for NuvaRing by directing you to this recent article, "October 2013 NuvaRing Label Change: Warnings And Precautions Section Sets Forth Two Competing Medical Studies About Side Effects".
My law firm has been involved with the NuvaRing litigation since it started in 2007. We will continue to monitor the NuvaRing litigation and report significant developments as they become publicly available.